Study to Test a Marketed Drug (MK0462) in the Early Treatment of Acute Migraine
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Migraine
Intervention: rizatriptan benzoate (Drug); Comparator: placebo (unspecified) (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
The purpose of this study is to test the effectiveness of a marketed drug in the early
treatment of an acute migraine attack.
Clinical Details
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Percentage of patients who are pain freeTolerability as measured by subjective adverse experience reporting
Secondary outcome: Percentage of patients with 24hr sustained pain freedom, associated symptoms, and use of rescue medication
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Greater than one year history of migraine
- Attacks typically mild when they begin and progress to moderate or severe
- Experience 1-4 migraine attacks per month
Exclusion Criteria:
- More than 15 headache days per month
- Heart disease
- Uncontrolled high blood pressure
Locations and Contacts
Additional Information
Starting date: August 2007
Last updated: February 27, 2008
|
